Federal regulators have highlighted a rare eye condition associated with GLP-1 drugs while multiple drugmakers shared clinical milestones. Beam Therapeutics announced that its CRISPR therapy risto-cel met its primary trial goal by preventing severe pain crises in sickle cell disease patients for a minimum of 12 months. With a regulatory filing planned as early as the end of this year, other developers are also making progress, such as PepGen releasing promising early muscular dystrophy data.
Key points
Regulatory officials are actively monitoring and flagging safety risks connected to GLP-1…: Regulatory officials are actively monitoring and flagging safety risks connected to GLP-1 medications.
Beam Therapeutics plans to submit an FDA marketing application for its sickle cell therap…: Beam Therapeutics plans to submit an FDA marketing application for its sickle cell therapy as early as this year.
Early clinical data show encouraging treatment progress for patients diagnosed with a com…: Early clinical data show encouraging treatment progress for patients diagnosed with a common type of muscular dystrophy.
Sources checked by our analysis pipeline: 1
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got lots of news that we’ll get straight into.
The need-to-know this morning
- Beam Therapeutics said its CRISPR-based treatment for sickle cell disease achieved the primary goal of a pivotal clinical trial — freedom from severe pain crises for at least 12 months. No detailed data were disclosed, but Beam said it would file an FDA marketing application for the therapy, called risto-cel, as soon as the end of this year.
PepGen shows promising data for muscular dystrophy
The biotech company PepGen said this morning that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a commmon type of muscular dystrophy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Food and Drug Administration has issued a warning that GLP-1 drugs may pose a risk of a rare condition that causes vision loss. While the risk appears to be small and current data remains mixed, the agency wants patients to be aware of the potential complication.
Federal regulators have cleared Bayer's novel therapy Sunharbo to prevent recurrent strokes without triggering the severe bleeding risks associated with traditional blood thinners. Concurrently, the agency issued an official warning alerting patients and physicians that popular GLP-1 treatments may cause a rare condition that leads to sudden vision loss. These actions address critical gaps in secondary stroke management while establishing new safety protocols for widely prescribed metabolic medications.
The pharmaceutical giant intends to submit a supplemental application to federal regulators to expand treatment options for patients managing bipolar disorder. Moving forward with this regulatory submission allows the company to pursue a broader therapeutic reach within mental health care. Success in this regulatory step could establish the medication as an approved intervention across additional stages of the psychiatric condition.